Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant Effect on Dabigatran PK in Healthy Participants
NCT05471817Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elinzanetant in vasomotor symptoms, sponsored by Bayer. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Curve at 72 hours. Started Aug 2022; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05471817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471817.